In our study, teriflunomide reduced the levels of IgG antibody titers against EBNA-1 and VCA of EBV and IgG and IgM against HHV-6 after 6 months of treatment in a real-life cohort of Spanish MS patients. Here, CD40LG is linked to myeloid sarcoma.